HC Wainwright Reiterates Buy Rating on Opus Genetics
Opus Genetics receives a buy rating reiteration from HC Wainwright with an $8.00 target.
Key Points
- HC Wainwright reiterated its buy rating for Opus Genetics, Inc. (IRD) on June 17, 2026, with a price target of $8.00.
- Shares of NasdaqCM:IRD traded at $4.14, with a market cap of about $335.2 million and a 52-week range between $0.90 and $5.81.
- Analyst consensus is strong buy with a mean target price of $10.47, while insiders sold shares recently at prices around $5.20.
HC Wainwright has reiterated its buy rating for Opus Genetics, Inc. (IRD), setting a price target of $8.00. This reiteration came on June 17, 2026, as analyst Matthew Caufield expressed continued confidence in the company's prospects.
Other Institutional Activity in Opus Genetics
Several other funds have shown interest in Opus Genetics. Caligan Partners LP added 6,075,028 shares, bringing its total to 6,075,028 shares valued at approximately $27.6 million. Adage Capital Partners GP, L.L.C. significantly increased its holdings by 4,924,779 shares to a total of 6,029,775 shares, worth about $27.4 million. Meanwhile, Millennium Management LLC boosted its position by 627,882 shares, ending with 2,630,432 shares valued at $11.97 million.
Opus Genetics Stock Snapshot
Shares of NasdaqCM:IRD recently traded at $4.14. Opus Genetics has a market cap of roughly $335.2 million. The stock's 52-week range spans from $0.90 to $5.81, with a 50-day moving average of $4.77 and a 200-day moving average of $3.15. The company maintains a strong liquidity position with a current ratio of 7.13 and a quick ratio of 6.71.
Recent Earnings
Opus Genetics reported revenue of $11.98 million, although this reflects a decline of 50.6% year-over-year. The company is not currently profitable, with a net margin of 0% and a return on equity of -75.95%. The next earnings report is anticipated on August 11, 2025.
Insider Buying and Selling at Opus Genetics, Inc.
Recent insider activity includes several sales. On May 18, 2026, Foundation Fighting Blindness Retinal Degeneration Fund sold 1,700,000 shares at an average price of $4.35. On April 23, 2026, various executives, including CEO George Magrath, sold shares at prices around $5.20.
Analysts Set New Price Targets
On June 17, 2026, HC Wainwright & Co. reiterated its buy rating for Opus Genetics with an $8.00 price target. Earlier, on June 4, 2026, Guggenheim initiated coverage with a buy rating and a $16.00 target. The consensus among analysts is a strong buy, with a mean target price of $10.47 based on 17 opinions.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and other ophthalmic disorders. Based in Durham, North Carolina, and led by CEO Dr. George Magrath, the company is advancing several therapies, including OPGx-LCA5 and OPGx-BEST1, through clinical trials. Founded in 2018, Opus Genetics aims to restore vision and prevent blindness through innovative treatments.
Bottom Line
HC Wainwright's reiterated buy rating and $8.00 target underscore ongoing confidence in Opus Genetics' potential. Investors track these ratings closely, although it's important to remember that analyst opinions are forward-looking and subject to change. The company's focus on gene therapies in the biotechnology sector offers both opportunities and challenges.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.